期刊
FUTURE ONCOLOGY
卷 15, 期 21, 页码 2479-2488出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0888
关键词
cancer-specific death; competing risk nomogram; SCLC; SEER
类别
资金
- National Key R&D Program of China [2016YFC0905500, 2016YFC0905503]
- Science and Technology Program of Guangdong [2017B020227001]
- Science and Technology Program of Guangzhou [201607020031, 201704020072]
Aim: Stage I small-cell lung cancer (SCLC) is a potentially curable disease that needs timely and multidisciplinary management. The aim of this study was to evaluate the probability of cause-specific mortality for patients with stage I SCLC. Material & methods: We identified patients in the SEER database and constructed a proportional subdistribution hazard model to evaluate cancer-specific mortality. A nomogram was built based on Fine and Gray competing risk regression model. Results:A total of864 stage I SCLC patients were identified. The 5-year cumulative incidence of SCLC-specific mortality was 56.2%, while that for other causes of death was 17.3%. The c-index for the prognostic prediction model was 0.66. Besides, the nomogram was well calibrated. Conclusion: Our nomogram might serve as a reference for clinicians when evaluating the prognosis of stage I SCLC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据